H2AX and plasma cell myeloma: In line with this interpretation, bortezomib strongly induced γ-H2AX accumulation after 24 h of treatment in myeloma cells across six validation samples of newly diagnosed patients (Fig. 6g), notably higher than the γ-H2AX levels induced in the same samples by the DNA-damaging agent bendamustine (Extended Data Fig. 7a).